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Abstract
Thioacetamide (TA) has long been known as a hepatotoxicant whose bioactivation requires S-
oxidation to thioacetamide S-oxide (TASO) and then to the very reactive S,S-dioxide (TASO2).
The latter can tautomerize to form acylating species capable of covalently modifying cellular
nucleophiles including phosphatidylethanolamine (PE) lipids and protein lysine side chains.
Isolated hepatocytes efficiently oxidize TA to TASO but experience little covalent binding or
cytotoxicity because TA is a very potent inhibitor of the oxidation of TASO to TASO2. On the
other hand hepatocytes treated with TASO show extensive covalent binding to both lipids and
proteins accompanied by extensive cytotoxicity. In this work, we treated rat hepatocytes with
[14C]-TASO and submitted the mitochondrial, microsomal and cytosolic fractions to 2DGE which
revealed a total of 321 radioactive protein spots. To facilitate the identification of target proteins
and adducted peptides we also treated cells with a mixture of TASO/[13C2D3]-TASO. Using a
combination of 1DGE- and 2DGE-based proteomic approaches, we identified 187 modified
peptides (174 acetylated, 50 acetimidoylated and 37 in both forms) from a total of 88 non-
redundant target proteins. Among the latter, 57 are also known targets of at least one other
hepatotoxin. The formation of both amide- and amidine-type adducts to protein lysine side chains
is in contrast to the exclusive formation of amidine-type adducts with PE phospholipids.
Thiobenzamide (TB) undergoes the same two-step oxidative bioactivation as TA, and it also gives
rise to both amide and amidine adducts on protein lysine side chains but only amidine adducts to
PE lipids. Despite their similarity in functional group chemical reactivity, only 38 of 62 known TB
target proteins are found among the 88 known targets of TASO. The potential roles of protein
modification by TASO in triggering cytotoxicity are discussed in terms of enzyme inhibition,
protein folding and chaperone function, and the emerging role of protein acetylation in
intracellular signaling and the regulation of biochemical pathways.
Introduction
Thioacetamide (TA) and thiobenzamide (TB) are representatives of a large group of
thiocarbonyl compounds, many of which are hepatotoxic.1–6 In rats, the toxicity of TB stems
from the covalent modification of lysine side chains on cellular proteins by its reactive S,S-
dioxide metabolite,7 accompanied by extensive modification of the amine group on cellular
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PE phospholipids.8 Among protein lysine groups both benzamide and benzamidine
modifications are formed, whereas only benzamidine modifications are observed on the PE
phospholipids.
TA and its initial metabolite thioacetamide S-oxide (TASO) elicit a variety of hepatotoxic
responses in rats depending on the dose and duration of administration.5, 9 TASO is strongly
cytotoxic to isolated rat hepatocytes in vitro, yet TA is not, despite the fact that rat
hepatocytes readily convert TA to TASO. This is due to the fact that TA is a potent inhibitor
of the oxidation of TASO to its reactive S,S-dioxide metabolite TASO2.5 By analogy with
TB, the metabolism of TA and TASO in vivo leads to the formation of acetamide
derivatives on protein lysine side chains.10, 11 In isolated hepatocytes, metabolism of TASO
leads to extensive modification of both protein lysine side chains and the amine groups of
PE lipids.6 The lysine adducts comprise both acetamide and acetamidine modifications,
whereas the PE lipid adducts comprise exclusively acetamidine groups. In hepatocytes, this
covalent binding precedes the appearance of cytotoxic effects, and both are prevented by TA
and other compounds that block the oxidative metabolism of TASO.5
The main objectives of this work were to characterize the reactive metabolite target
proteome of TASO in rat hepatocytes, to compare it to those of other known
hepatotoxicants, and to identify individual sites of protein modification and the structures of
the adducts formed. We incubated freshly isolated rat hepatocytes with either [14C]-TASO
or [13C2D3]-TASO and analyzed subcellular fractions by 1D- and 2D gel electrophoresis
followed by tryptic digestion and LC-MS/MS analysis. Herein we report the identification of
88 proteins targeted by the reactive metabolite of TASO. This is the largest set of target
proteins known for any single bioactivated chemical.12 While many reactive metabolite
targets have been identified at the protein level,12 the characterization and sequencing of
adducts at the peptide level has only rarely been achieved. However, because of the
efficiency of cellular protein modification by TASO metabolites, we are also able to report
the identification and sequencing of peptides comprising 187 different sites of adduction
among the 88 TASO metabolite target proteins. Finally, we compare the list of TASO
metabolite targets to the range of others in the reactive metabolite target protein database12
and comment on the potential contribution of their modification to the ensuing toxicity.
Experimental Procedures
Materials
TASO, [14C]-TASO (1.95 Ci/mol) and [13C2D3]-TASO were synthesized according to a
literature procedure.13 Deionized water (resistivity 18.2 MH/cm) was used for the
preparation of all solutions and buffers. Other materials and suppliers were as follows:
Collagenase type IV, Percoll and 4-vinylpyridine (sigmaaldrich.com); HPLC grade solvents
and analytical grade inorganic salts (fishersci.com); Dulbecco’s modified Eagle’s medium
(DMEM) and phosphate-buffered saline (PBS, pH 7.4) (cellgro.com); sequencing grade
trypsin (rocheusa.com); Protease Inhibitor Cocktail (PIC), Sequenal grade urea and 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS, piercenet.com); silica
gel TLC plates, type LK5DF with a pre-adsorbent loading zone (whatman.com); Tris, SDS,
glycine, Sequi-blot PVDF membranes (0.2 micron pore size), Bradford reagent, and
Precision Protein Standards (biorad.com); other electrophoresis supplies (gehealthcare.com).
Preparation of Isolated Hepatocytes
Male Sprague-Dawley rats from Charles River Laboratories (criver.com) were housed in a
temperature and humidity controlled room with a 12 h light/dark cycle and ad libitum access
to food and water. All animal husbandry protocols were in accordance with the NIH
Koen et al. Page 2













Guide.14 Experimental procedures were approved by the University of Kansas Institutional
Animal Care and Use Committee. Hepatocytes from non-induced male Sprague-Dawley rats
(175–275 g) were isolated using a previously described protocol.15 Initial cell viability (85–
95%) was assessed using trypan blue exclusion. After isolation, the cells were transferred to
the incubation medium A (DMEM supplemented with 1% (v/v) Pen-Strep, insulin (4 mg/L),
5% FBS, 100 nM dexamethasone, and 2 mM L-glutamine (all from Gibco-Invitrogen,
www.invitrogen.com).
Detection of acetylated proteins by western blotting
Freshly isolated hepatocytes were plated on 6-well collagen coated plates and allowed to
attach for 3 hours as described,5 after which the cells were treated with TASO (3 mM) in
nutrient-rich WME [Williams’ Medium E supplemented with 1% ITS, 1% Pen-Strep, 2 mM
L-glutamine, and 100 nM dexamethasone (3.0 mL/well)] ) for 10, 30 or 60 min. Control
(UT) cells were incubated for 60 min in the same medium without TASO. Cells were treated
with RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris, pH 8.0) supplemented with 1X protease and phosphatase inhibitors (Thermo
Scientific). Cell lysates were subjected to sonication followed by centrifugation for 10 min
at 20,000 × g at 4°C. Aliquots of the resulting supernatants containing identical amounts of
protein were subjected to electrophoresis and transblotting as described.5 Blots were then
probed with a mouse monoclonal antibodies cocktail containing anti-acetylated lysine
(15910) (Novus Biologicals, Cat. # NB100-78428), Ac-lysine (AKL5C1) (Santa Cruz, Cat.
# sc-32268), acetylated-lysine (Ac-k-103) (Cell Signaling, Cat. # 96815), and acetylated
lysine (Thermo Scientific, Cat. # MA1-2021) antibodies at a 1:2000 dilution for 2 h. The
blots were then treated with HRP-conjugated anti-mouse secondary antibody (Santa Cruz,
Cat#sc-2005) and Pierce ECL Western Blotting Substrate according to the manufacturer’s
protocol. The reaction was visualized by exposing the blots to X-ray films.
Hepatocyte Incubations
For studies aimed at detection of adducted proteins, [14C]-TASO (10 mM, 1.95 Ci/mol) was
incubated with hepatocytes freshly isolated from two rats (1 × 107 live cells/mL in a total
volume of 1.7 or 2.3 mL, respectively, of medium A) in 50 mL round-bottom screw-cap
culture tubes. Before adding the hepatocytes to the tubes, the required amounts of TASO
were deposited by evaporation from a methanol solution. Incubations were shaken at 140 Hz
in a water-bath at 37 °C under an atmosphere of O2/CO2 (95:5) for 4–5 h. Immediately after
the incubation, the medium was removed by centrifugation (3 min at 100 g) and the cell
pellets were frozen at −80°C. Hepatocytes from two separate incubations were pooled to
give a total of 1 × 108 cells prior to subcellular fractionation (see below). In parallel, small
scale incubations were conducted for quantitative assessment of covalent binding by protein
precipitation and washing on 3MM filter paper.5 For identification of protein adducts, a 10:6
mixture of [13C2D3]-TASO/TASO was substituted for radiolabeled TASO and incubations
were conducted identically. Hepatocytes from four different preparations were incubated
separately, centrifuged, frozen and pooled (a total of ca. 2.5 × 108 cells) prior to their
fractionation as described below.
Preparation of Subcellular Fractions of Hepatocytes
The incubated cells were homogenized and fractionated by differential centrifugation with
all procedures performed at 0–4 °C. The cell pellets were thawed and resuspended by gently
pipetting with a small volume of homogenization buffer (50 mM Tris-HCl, pH 7.4, 150 mM
KCl, 2 mM EDTA) containing proteinase inhibitor cocktail. The resulting suspensions were
pooled and homogenized manually (15–20 pestle strokes) in a Potter-Elvehjem (glass-
Teflon) tissue grinder maintained in an ice-bath. The final ratio of cell pellet/buffer was ca.
1:1.85 (v/v). The homogenate was centrifuged at 800 × g for 15 min. The resulting pellet
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(cell debris/nuclei) was resuspended by pipetting with a small volume of a storage buffer
(100 mM KH2PO4 (pH 7.4), 1 mM EDTA, 1 mM DTT, 20% (v/v) glycerol). The 800g-
supernatant was further centrifuged at 9500 × g for 20 min. The resulting pellet (P9-fraction,
mitochondria) was resuspended as above, while the supernatant (S9 fraction) was further
centrifuged at 100000 × g for 60 min. The resulting clear supernatant (S100, cytosol) was
carefully removed, leaving some turbid supernatant (collected separately). The pellet (P100,
microsomes) was resuspended by homogenization with storage buffer using a Teflon pestle
directly within the centrifuge tubes. In experiments using 14C-TASO, clear cytosol was
submitted to several successive rounds of ultrafiltration (Amicon Ultra-4 Ultracel-5k
ultrafiltration centrifuge tubes) against 20 mM KH2PO4 (pH 7.4) containing 0.25 mM
EDTA, in order to remove soluble radiolabel. All the subcellular fractions were stored in
aliquots at −80°C until used.
Electrophoresis, Phosphorimaging, and In-gel Digestion
These standard procedures were carried out essentially as described earlier.16–18
Mass Spectrometry of Tryptic Digests and Protein Identification
Digested protein samples were analyzed by LC-MS/MS using a NanoAcquity
chromatographic system (Waters Corp., Milford, MA) coupled to an LTQ-FT mass
spectrometer (ThermoFinnigan, Bremen, Germany). Peptides were separated on a reverse-
phase C18 column, 15 cm, 300 μm I.D. (Thermo Acclaim PepMap300, 300 Å, 5 μm). The
solvents were A (99.9% H2O and 0.1% formic acid) and B (99.9% acetonitrile and 0.1%
formic acid). A gradient was developed from 1 to 40% B in 50 min, increased to 95% B in 4
min, and held at 95% B for 5 min at a flow rate of 10 μL/min. The NanoAquity UPLC
Console (Waters Corp., version 1.3) was used to control the injections and gradients. Data
dependent acquisition method for the mass spectrometer (configured version LTQ-FT 2.2)
was set up using Xcalibur software (Thermo Scientific, version 2.0). Full spectrum survey
scans were acquired at a resolution of 50,000 with an Automatic Gain Control (AGC) target
of 5 × 105. Five most abundant ions were fragmented in the LTQ with an AGC target of 2 ×
103 or a maximum ion time of 300 ms. The ion selection threshold was 500 counts. The
LTQ-FT scan sequence was adapted from Olsen and Mann.19
Raw data files were converted into Mascot generic format using MassMatrix MS data file
Conversion Tools (version 3.9). The data were then presented to Mascot search engine
(Matrix Science, version 2.3) for peptide/protein identification using UniProtKB database
(http://www.uniprot.org). In addition, the Sequest algorithm within Proteome Discoverer
software (Thermo Scientific Inc., version 1.3) and the X!Tandem algorithm
(www.thegpm.org) were also used for identifying proteins and their adducts. Fragment ion
mass tolerance was set to 0.20 Da and parent ion tolerance was set to 20.0 ppm. The
pyridylethyl (+105) derivative of cysteine residues was specified as a static modification,
and the “light” (+42) and “heavy” (+47) acetyl derivatives and the “light” (+41) and “heavy”
(+46) acetimidoyl derivatives of lysine residues as well as of N-terminal amino acid residues
were specified as variable modifications. Scaffold software (Proteome Software Inc., version
3.6) was used to combine and validate the results of protein identifications. For unmodified
peptides, identifications were accepted if they could be established at greater than 95%
probability as specified by the Peptide Prophet algorithm.20 Additional criteria such as mass
accuracy and the presence of light/heavy ion pairs in MS1 spectra were also considered for
confirming identities of adducted peptides (see Results and Discussion section). Protein
identifications were accepted if they could be established at greater than 99% probability
and contained at least 2 identified peptides. Protein probabilities were assigned by the
Protein Prophet algorithm.21 Quantitative ratios of peptide adducts were derived from the
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chromatographic areas of their monoisotopic peaks using Qual Browser of Xcalibur
software (Thermo Scientific Inc., version 2.1).
Results and Discussion
Freshly isolated rat hepatocytes were incubated with [14C]-TASO to facilitate locating
adducts on 2D gel electrophoresis, and with [13C2D3]-TASO to generate adducts for mass
spectral analysis. As reported previously,6 TASO gives rise to high levels of adduction in
both the protein fraction (20 nmol-equiv./million cells) and the lipid fraction (37 nmol-
equiv./million cells). The rapidity and extent of protein acetylation in TASO-treated
hepatocytes is illustrated in Figure 1 which shows a western blot of total cellular lysate
proteins made using a cocktail mixture of four different anti-acetyllysine monoclonal
antibodies.
Incubation of cells with [14C]-TASO
Two batches of freshly isolated hepatocytes (a total of ca. 108 live cells) were incubated
with a cytotoxic concentration of [14C]-TASO (10 mM), then pooled and pelleted. After
homogenization and differential centrifugation, the crude mitochondria, microsomes and
cytosol fractions were found to contain 80, 86 and 125 nmol-equiv./mg protein, respectively.
As expected, a majority of the radiolabel found in the cytosol was removable by
ultrafiltration (Table 1); this probably represents unmetabolized TASO and its soluble
metabolites. Hence, the actual covalent binding in these fractions is probably lower than
suggested by these ratios of radioactivity to protein. The concentration of TASO we used
causes some cytotosicity, as reflected by ca. 50% leakage of lactic dehydrogenase into the
medium (unpublished results; see also ref. 5). While this may impact the distribution of
radioactivity among the subcellular fractions, it has no impact on the isolation and
identification of target proteins.
Individual subcellular fractions were submitted to 2DGE followed by trans-blotting to a
PVDF membrane. The membrane was subsequently stained to locate protein spots and
phosphorimaged to locate radioactive spots. Among hundreds of protein spots seen on the
blots, many (but not all) show the presence of radiolabel (Supporting Information, Figures
S1–S3). Interestingly, some of the most abundant protein spots contained little or no
detectable radioactivity. Such selectivity of targeting and adduction has been also observed
with other hepatotoxicants,16 although the reasons behind it are not well understood.
In addition to numerous discrete radioactive protein spots, the phosphorimages of the blots
of the mitochondrial and microsomal fractions show a conspicuous smear of radioactivity in
the low MW/low pI area that is not stained by Coomassie. A similar pattern of radioactive
but apparently non-proteinaceous material was observed on blots of 2D gels of liver
microsomes from TB-treated rats,7 liver mitochondria from BB-treated rats,16 and total
protein from human hepatocytes incubated with tienilic acid.22 Because this material is
observed only in the membrane fractions and does not stain with Coomassie, we speculated
that it might be some type of adducted lipid material. Although TASO and TB are well
known to generate adducts on the amine group of PE lipids,6, 8 it is not clear whether these
adducts could account for the low MW/low pI material in the phosophorimage and we have
not pursued this question further.
Incubation of cells with [13C2D3]-TASO
To generate an isotopic signature that would facilitate detection of adducted peptides by
mass spectrometry we also incubated freshly isolated hepatocytes with a mixture of TASO
and [13C2D3]-TASO (10:6 mol ratio). The incubated cells were homogenized and
centrifuged to obtain the mitochondria, microsomes and cytosol, and a portion of each
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fraction was subjected to 2D gel electrophoresis as described above (6 replicate gels per
fraction). Representative Coomassie-stained gels are shown in Figures S1–S3. Using the
phosphorimage of the 14C blot as a guide, spots corresponding to radioactive target spots
were excised, pooled and subjected to in-gel digestion and LC-MS/MS analysis. Because
some proteins, particularly membrane proteins, do not separate well on 2DGE,23 a second
portion of each subcellular fraction was subjected to 1D SDS-PAGE (Figure S4), after
which each lane was cut into 18 bands. Corresponding bands were pooled and subjected to
in-gel digestion followed by LC-MS/MS analysis.
Target protein identification by 2DGE and LC-MS/MS
One or more proteins were identified in each of 117 spots from the cytosol fraction, 112
spots from the mitochondrial fraction and 92 spots from the microsomal fraction (Table 2).
Because some spots contained more than one identifiable protein, the total number of
proteins identified in target spots (1061; Table 2 line 5) exceeded the total number of such
spots (396). Approximately 25% of the spots analyzed contained only a single protein;
hence that protein was taken to be a target protein even if no adducted peptides were
observed. In contrast, the observation of multiple proteins in a single spot obviously raises a
question about the identity of the actual target protein(s) unless adducted peptides are
observed. This becomes especially important when one uses 1DGE because of its lower
resolving power compared to 2DGE (see below).
To identify adducts, we first searched the mass spectra of the digests of 2DGE spots against
a protein database for the presence of light/heavy pairs of acetyl- or acetimidoyl-peptides
(i.e., M+42/M+47 or M+41/M+46, respectively). Examples of MS/MS spectra of peptides
displaying the expected isotopic signature in both types of adducts are shown in Figure S5.
The Scaffold peptide probability scores for adducted peptides were generally at the 95%
level. In a very few cases, low scores occurred when there was ambiguity in a sequence tag
that would be required to correctly localize the modification to a specific amino acid
(reflected in the Mascot Delta score) even though the identity scores for the reported
adducted peptide was high. Thus the lowest probability scores were for adducts either
involving one of a pair of two adjacent lysines, or adducts on a N-terminal residue.
Independent of peptide probability scores, all the adducted peptide hits were carefully
examined for sequence tags and the accuracy of their MS1 mass measurement (Table S4).
The average error for adducted peptides was 2.3 ppm. An additional reliability criterion for
accepting identities of adducted peptides was presence of light/heavy peptide ion pairs in the
MS1 spectra, as shown by the example in Figure S6. When such pairs were found the
intensities of monoisotopic peaks were taken to estimate light/heavy ratios for both acetyl-
and acetimidoyl- derivatives.
The observation of both members of the isotopic pair indicates that the adduct is definitely
TASO-derived, but in some cases only the light member of the light/heavy adduct pair was
observed by MS/MS. Because protein acetylation is a well-known endogenous modification,
the appearance of a M+42 peptide without a corresponding M+47 partner does not
necessarily indicate a target protein. When we observed such occurrences the proteins were
not counted as target proteins unless the modification occurred at a position neither known
nor predicted to be endogenously acetylated (see proteins 12 and 65 in Table S1 for
examples).
In contrast to the ambiguity of observing M+42 as the sole modification, we observed no
instances of M+47 in the absence of a corresponding M+42. On the other hand, since protein
acetimidoylation is not an endogenous process, the observation of either an M+41 or an M
+46 acetimidoyl adduct on a lysine residue provided a clear indication that its parent protein
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was a target for the reactive metabolite of TASO. Of the 88 target proteins identified, 21, 29
and 38 had zero, one or more than one observed modifications, respectively.
Target protein identification by 1DGE and LC-MS/MS
Because of the lower resolution of 1D gels, digests of some of the bands cut from the gel
contained up to 25 identifiable proteins. The total numbers of proteins identified in the three
subcellular fractions after 1D vs. 2D gel electrophoresis are given in Table 2. We also
observed many adduct-containing peptides in the digests of the 1D gel fractions. This is
critically important for differentiating target proteins from non-target proteins in the
complex digest mixtures. While many of the target proteins identified from digests of 1DGE
bands are also observed in digests from 2DGE spots, several target proteins were identified
only from the 1DGE data. Among these are two isoforms of cytochrome P450 (one of
which, CYP2E1, is known to be involved in the bioactivation of TA and TASO),5, 24 two
isoforms of UGT, a mitochondrial fission protein, carboxylesterase 3 (ES-10), and several
others. Although P450 and UGT enzymes have previously been identified as reactive
metabolite targets, this is the first time that an adducted peptide from a P450 or UGT
enzyme has been observed.
Chemistry of adduct formation—As shown in Scheme 1, the reactive metabolite of
TASO is a S,S-dioxide that tautomerizes to form an iminosulfinic acid capable of reacting
with nucleophilic amine groups on protein lysines and PE lipids to form an amidine
derivative. Amidines are chemically stable and do not hydrolyze to amides under ordinary
conditions. However, the iminosulfinic acid can undergo hydrolysis to form an acylsulfinic
acid capable of acylating amines to form an amide derivative. An alternative hydrolysis
pathway leads to acetamide as a stable metabolite. Curiously, while TB and TASO each give
rise to both amide and amidine adducts on cellular proteins, their cellular PE targets show
exclusively amidine modifications.5, 8 In this study peptide adducts were observed and
identified at 187 different positions on 67 of the 88 non-redundant TASO target proteins
(Table 2, Table S1). At 36 of these positions both amide and amidine adducts were
observed. As summarized in Table 2 and detailed in Table S1, a total of 173 acetylated and
51 acetimidoylated peptides was observed, thus the overall ratio of acetylation to
acetimidoylation was 3.4. A similar ratio (ca. 3) was previously observed for benzoylation
vs. benzimidoylation of liver proteins from TB-treated rats.7 A majority of the adducts of
both types were formed on the ε-amino groups of lysine side chains, although both types
were also observed on N-terminal amine groups, especially proline.
Comparison of observed vs. predicted sites of acetylation—The UniProt database
predicted 38 of our 88 target proteins to have one or more (range 1–15) sites of lysine
acetylation (Table S1), whereas we actually observed 54 proteins with ≥1 acetyl lysine
(AcK) modifications (range 1–15). Out of a total of 152 observed AcK sites among these 54
proteins, only 19 individual sites were predicted by UniProt. To look more closely at the
question of endogenous vs. xenobiotic acetylation we examined six representative target
proteins for which the MS/MS sequence coverage was ≥ 45% and for which numerous
adducted peptides were observed (Table S2). In all cases where a lysine modification was
observed, peptides containing the same lysine in unmodified form were also observed. In
addition, some of the predicted acetylation positions were observed in both acetylated and
acetimidoylated forms. Although peak intensity ratios in mass spectrometry are not reliable
indicators of molar ratios, it is worth noting that in virtually every case, the intensity of the
unmodified peptide was 10–100 times as great as that of the modified peptide. On the other
hand the ratio of light to heavy acetyl groups in individual AcK-containing peptides was
2.49 ± 1.02 (mean ± sd, n = 24), and the corresponding ratio for amidine groups was 2.27 ±
0.44. These values are a little higher than the 1.67 ratio of the starting TASO. That the
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light:heavy ratio in the observed AcK adducts is higher than that of the starting TASO is
consistent with the occurrence of small and variable amounts of endogenous acetylation at
these sites. However, this suggestion must be tempered by the observation that the
light:heavy ratio is also elevated among the acetimidoyl lysine adducts, where no
endogenous contribution is possible. It should be noted that among the various acetylomes
that have been characterized to date,25–28 none report data on the relative degree (mole
fraction) of acetylation at any given site on the protein. This is largely for two reasons: one
is the uncertainty about relative response factors for acetylated vs. unmodified peptide
mentioned above; the other is that in most cases samples were enriched prior to analysis
using an anti-AcK antibody, thereby precluding measurement of the unmodified peptide.
Comparison of TASO-treated rat vs. normal human acetylomes—Zhao et al.
detected more than 1300 acetylated peptides representing 1047 distinct proteins, or slightly
more than one acetylated peptide per protein, in normal human liver.29 Of the 88 rat proteins
identified as targets for TASO metabolites, 31 had human orthologs that also appeared in the
list reported by Zhao et al. We selected 20 of the 31 rat proteins to analyze with respect to
acetylation status as compared to predictions by UniProt and observations by Zhao et al.
(Table S3). Only three of the 20 acetylated human peptides observed by Zhao et al. were
predicted by UniProt to be acetylated. Of the 20 orthologous rat proteins, two did not have a
lysine at the corresponding position. Among the other 18 rat peptides UniProt predicted five
cases of acetylation, but none of these was observed. We observed only one case of
acetylation among the 18 rat peptides (cytochrome b5, line 5). The same acetylated peptide
was also observed by Zhao et al., but neither case was predicted by UniProt. However, 14 of
the other 18 rat peptides were observed in unmodified form (Table S3) while in three cases
no corresponding rat peptide was observed.
Summary of TASO target protein and adduct identification
By applying the search and acceptance criteria mentioned above we identified a total of 362
adducted peptides derived from a total of 1061 target and non-target proteins (Table 2 line
5). However, there is considerable redundancy within these data resulting from the imperfect
separation of the three subcellular fractions via single successive centrifugation steps, from
the parallel use of both 1D and 2D electrophoresis, and because it is not uncommon for
some proteins to appear in several distinct, well-separated spots on 2D gels.16, 30, 31 After
correcting for this redundancy a total of 187 distinct sites of adduction were observed among
a total of 88 non-redundant target proteins. The latter are listed in Table 3, grouped under
several subheadings according to their known cellular function; the details of the
information used for their identification and the sites and nature of the adducts observed in
each case are given separately in Tables S1 and S4. Of the 88 targets identified, only 21
occurred in single-protein spots on 2D gels; the others were identified by observing
adducted peptides in digests of materials from 1D and/or 2D gels.
Potential toxicological consequences of protein modification by reactive
metabolites of TASO—The largest subgroup of TASO target proteins consists of 25
enzymes of intermediary metabolism plus 13 enzymes of drug metabolism. While it is not
known whether adduction by TASO actually inhibits any of these enzymes, enzyme
inhibition per se is not likely to be a major cause of cytotoxicity in most cases, because for
any given protein the average extent of adduction is very low. For example, whereas
covalent binding of TASO can reach 20 nmol/mg protein, typical levels for other well
known hepatotoxicants (e.g., acetaminophen or bromobenzene) are usually around 1–2
nmol/mg protein, and the levels for many other drugs are even lower.8, 32, 33 Thus, for a 50
kDa protein adducted to a level of 1 nmol/mg protein, only five molecules out of 100 would
actually be modified. For most pathways in most cells, 5% inhibition would not likely lead
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to acute cytotoxicity, especially if that enzyme was not the rate-limiting step in the pathway.
It would seem, therefore, that for covalent adduction of proteins to elicit major biological
effects, some form of amplification, such as that seen in immunological responses or cell
signaling cascades, would be required. Immunological reactions in patients can be triggered
by metabolites in some cases (e.g. halothane or tienilic acid),34–37 but for most
metabolically activated pro-toxins one must look to other potential mechanisms of response
amplification.
One such mechanism may arise through the effects of protein adduction on protein-protein
interactions (PPIs). Proteins in cells exist in an extremely crowded environment owing to
their high total concentration.38, 39 Covalent adduction can alter the size, hydrophobicity and
even the ionic charge of protein side chains. Such changes can alter the tertiary or even
quaternary structure of proteins, leading to the inhibition of essential PPIs or the inadvertent
generation of new ones (e.g. with chaperones and heat shock proteins40–43 or with
components of intracellular signaling pathways). Extensive evidence implicates the
involvement of protein kinase-based signaling pathways such as extracellular signal-related
kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and nuclear factor kappa-B (NF-κB)
in cellular responses to toxic or reactive chemicals or metabolites.44–53 Malfolded proteins
disrupt ER function leading to activation of the unfolded protein reponse (UPR) and, in the
extreme case, to apoptosis.40, 54–56 Chaperones and heat shock proteins can protect cells
against these deleterious effects,57–59 but only up to a point, after which the cell commits to
apoptosis.48, 53
The second largest group of TASO targets consists of 18 proteins involved in protein folding
and/or stress response. Within this group PDI A1 and PDI A3 stand out by becoming
acylated at 10 and 15 different lysines, respectively, none of which is known to be a site of
endogenous acetylation.60 They are also the two most frequently reported targets for
reactive metabolites in the entire TPDB, with each being attacked by 12 different
chemicals.12 The PDIs represent a family of multifunctional enzymes that are major
components of ER protein quality control.61–63 They are induced as part of stress responses
and the unfolded protein response, and their induction (e.g., by heat stress) protects cells
against the cytotoxic effects of agents like acetaminophen.46, 59, 64 Whether their adduction
by reactive metabolites generally inhibits their function is not known, but it is known that
bovine PDI is adducted and inhibited by reactive electrophiles derived from lipid
peroxidation.65 One can speculate, therefore, that appending hydrophobic xenobiotic
adducts onto these proteins may impair their ability to function normally and thereby render
cells more susceptible to the harmful effects of protein adduction.
In recent years protein lysine acetylation has come to be recognized as an important
mechanism for regulating the activity, stability and half-life of many cellular proteins.66, 67
Large protein “acetylomes” have been described for Salmonella,27, Arabidopsis,28
Drosophila,68 human liver29 and several human cell lines.25, 26 Histone acetylation and
deacetylation regulate chromatin structure and the availability of DNA for transcription or
replication.69 Acetylation and de-acetylation is also a major mechanism for regulating the
activity of many metabolic enzymes, especially in mitochondria.70 Nearly 20% of
mitochondrial proteins exhibit nutrient-dependent lysine acetylation that modulates the TCA
cycle, the electron transport chain and oxidative phosphorylation, amino acid metabolism
and antioxidant defenses.26, 27 The sirtuin family of deacetylases depend on NAD+ as a
cofactor which therefore couples the energy- and redox status of the cell to the regulation of
metabolic enzymes.70 The X-box-binding protein 1 (XBP1), a key regulator of the unfolded
protein response, is itself regulated by protein acetylation,71 as are the activities of the
transcription factor p5369, 72 and the chaperone protein HSP90.73 Given the widespread
roles of protein acetylation in regulating cellular metabolism, it is not hard to imagine that
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the dramatic burst of protein acetylation that accompanies the oxidation of TASO in cells
(Figure 1) could lead to significant derangements of cellular homeostasis leading to cell
death. Collectively, it is our opinion that xenobiotic post-translational modifications inflicted
on stress response proteins, chaperones, and signaling- or regulatory proteins by chemically
reactive metabolites are likely to comprise major mechanisms by which chemically reactive
metabolites produce cellular injury.
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Figure 1. Western blot showing the time-dependent increase in acetylated protein lysine side
chains in rat hepatocytes treated with TASO
Rat hepatocytes (1.5 × 106 cells/well) in 6-well collagen-coated plates were treated with
TASO (3 mM) for the indicated times. The untreated (UT) control group was harvested at
the 60 min endpoint. Whole cell lysates and western blots to detect acetylated lysine and β-
actin were produced as described in Materials and Methods.
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Routes of formation and decomposition of TASO2.
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Table 3
Proteins identified as targets of TASO metabolites in rat hepatocytes.
Protein name Acc # a Source/methodb Also target forc
Intermediary metabolism (25 proteins)
3-ketoacyl-CoA thiolase A, peroxisomal P21775 Ct9, Mt8 (1D); Ct36, Mt47, 53-57;
Ms56 (2D)
3-ketoacyl-CoA thiolase B, peroxisomal P07871 Ct9 (1D), Ct56 (2D)
Adenosylhomocysteinase P10760 Ct10 (1D)
Alcohol dehydrogenase 1 P06757 Ct9 (1D) MDAB, TB, TEU
Aldehyde dehydrogenase family 8 member A1 Q9H2A2 Ct11 (1D)
Alpha-enolase P04764 Ct28-30; Mt44, Ms35,37 (2D) BB, MYCO, TB, DACT,
BHT
Arginase-1 P07824 Ct35, 36, 41; Ms53, 54 (2D) BB, TB, TIE
Betaine--homocysteine S-methyltransferase 1 O09171 Ct10, Mt9 (1D); Mt114 (2D) TEU
Carbamoyl-phosphate synthase P07756 Mt12-14, Ms14 (1D) TEU
Carbonic anhydrase 3 P14141 Ct7, Mt7 (1D); Ct21-23, 74-77;
Mt33, 34, 36, 96, 97, 99; Ms86 (2D)
APAP, BB, TB, VCN
Carboxylesterase 3 (ES-10) P16303 Mt10, Ms10 (1D) MOL, BB
Cytosol aminopeptidase Q68FS4 Ms34 (2D)
D-dopachrome decarboxylase P80254 Ct1-3, Mt2, 3, Ms3 (1D); Ct109,
112, 114, 116; Mt113-116; Ms112,
114, 117 (2D)
BB, TB, TIE
Fructose-bisphosphate aldolase B P00884 Ct9 (1D); Ct56, Mt44, 54 (2D) MYCO, TB, TEU
Fumarylacetoacetase P25093 Ms47, 48 BB, 4BP, TB, TIE




Glycine N-methyltransferase P13255 Ct8 (1D), Ct53, 54 (2D)
Hexose-6-phosphate dehydrogenase D4A7D7 Mt12 (1D)
L-Lactate dehydrogenase A-chain P04642 Ct8 (1D)
Long-chain-fatty-acid--CoA ligase 1 P18163 Mt11 (1D) TEU
Malate dehydrogenase, cytoplasmic O88989 Ct47, 49 (2D) 4BP, TB, TIE
Methylmalonate-semialdehyde dehydrogenase Q02253 Mt37 (2D) MYCO, TEU
Phosphoglycerate kinase 1 P16617 Mt50, Ms51 (2D) BB, TB, DACT
Triosephosphate isomerase P48500 Ct75 (2D) BB, 4BP, DACT, MYCO,
TIE
UMP-CMP kinase Q4KM73 Ct63, 66 (2D)
Protein synthesis (6 proteins)
40S ribosomal protein S13 P62278 Ms5 (1D)
40S ribosomal protein S2 P27952 Ct128 (2D)
DNA-directed RNA-polymerase III subunit RPC2 P59470 Ct82 (2D)
Elongation factor 1-alpha 1 P62630 Ct11, Mt12 (1D) BENZ, BHT, MYCO
Elongation factor 1-beta O70251 Mt68 (2D)
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Protein name Acc # a Source/methodb Also target forc
Ribonuclease UK114 P52759 Ct1-3, Mt2, 3 (1D); Ct109, 110;
Mt113, 115, 134; Ms112, 119 (2D)
BB, TB, MYCO
Protein folding/stress response (18)
10 kDa heat shock protein, mitochondrial P26772 Ct130 (2D) BENZ
60 kDa heat shock protein, mitochondrial P63039 Ct13 (2D) NAPH, TFEC, TEU,
DACT, 4BP, COC, BQ, 1,4-
NQ
78 kDa glucose-regulated protein P06761 Mt66,104; Ms9,10 (2D); Ms11 (1D) HAL, BB, NAPH, TB,
TEU, 4BP
Endoplasmic reticulum resident protein 29 (ERp29) P52555 Mt76, 81, 92; Ms73, 74, 79 (2D) BB, TB
Hypoxia up-regulated protein 1 Q63617 Ms13 (1D) TB
Heat shock cognate 71 kDa protein P63018 Ct13, Mt11 (1D) BB, MYCO, TB, BHT,
NAPH
Mesencephalic astrocyte-derived neurotrophic factor P0C5H9 Mt118, 120, 121; Ms92 (2D)
Peptidyl-prolyl cis-trans isomerase A P10111 Mt5 (1D); Ct98-102; Mt122,
125-128; Ms98-101 (2D)
TB
Peptidyl-prolyl cis-trans isomerase B P24368 Mt5, 6; Ms5 (1D); Mt118, 124;
Ms92, 94 (2D)
TB
Peptidyl-prolyl cis-trans isomerase FKBP1A Q62658 Mt3, Ms3 (1D); Mt130 (2D)
Peptidyl-prolyl cis-trans isomerase FKBP2 D3ZZR9 Mt2, Ms3 (1D); Mt135, Ms127 (2D) TB
Protein disulfide-isomerase (PDIA1) P04785 Mt10 (1D), Mt3, 5; Ms22 (2D) APAP, AMAP, BENZ,
NAPH, HAL, MCTP, BQ,
1,4-NQ, BB, 4BP, TB
Protein disulfide-isomerase A3 (ER-60) P11598 Mt10, Ms10 (1D); Mt23-29, 70, 71;
Ms11-15, 17, 18 (2D)
APAP, ATRZ, DACT,
NAPH, MCTP, BQ, 1,4-
NQ, BB, 4BP, MYCO, TB
Protein disulfide-isomerase A6 (CaBP1) Q63081 Mt47, Ms26 (2D) BB, TB, TEU
Stress-70 protein, mitochondrial (75 kDa GRP, mortalin) P48721 Mt8 (2D) 4BP, NAPH, DACT, TFEC,
BQ, 1,4-NQ
Stress-induced-phosphoprotein 1 O35814 Ct8-10 (2D) TB
T-complex protein 1 subunit beta Q5XIM9 Ms32 (2D)
UDP-glucose:glycoprotein glucosyltransferase 1 Q9JLA3 Mt14 (1D) HAL
Binding/carrier proteins (15)
Acyl-CoA-binding protein P11030 Ct126, 127, 129; Mt136; Ms121,
128 (2D)
TB
Alpha-1-antiproteinase P17475 Ms30, 31 (2D) NAPH, AMAP, TB
Alpha-tocopherol transfer protein P41034 Ct7 (1D)
Annexin A6 (Ca-BP 65/67) P48037 Ct13 (1D)
Apolipoprotein A-I P04639 Mt73, 75 (2D) BHT, TB
Calnexin P35565 Ms11 (1D)
Calreticulin P18418 Ms21, 23 (2D) APAP, HAL, TB
Destrin (Actin-depolymerizing factor) Q7M0E3 Ct86 (2D)
Fatty acid-binding protein, liver P02692 Ct1-3, Mt2,3, Ms3 (1D); Ct114,
115, 117, 118, 131; Mt113, 115,
117, 130, 131; Ms118, 122 (2D)
BB, TB, TIE
Histidine triad nucleotide-binding protein 1 P62959 Ct95 (2D)
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Protein name Acc # a Source/methodb Also target forc
Regucalcin Q03336 Ct8 (1D), Ct61 (2D) BB, TIE
Retinol-binding protein 4 P04916 Ms82 (2D)
Serotransferrin P12346 Mt19, Ms40 (2D) COC, TB
Serum albumin P02770 Ct1, 3-5, 7, 25-27; Mt11-17; Ms1-6,
8 (2D)
ATRZ, BB, 4BP, DCE, TIE,
TB, NAPH, BFP, FCXC
Transthyretin P02767 Mt110, 111; Ms113 (2D) BB, TB
Redox regulation (7 proteins)
Catalase P04762 Ct12, Mt11 (1D); Ct20; Mt30, 32,
34; Ms42-44 (2D)
4BP, TEU, TB
Glutathione peroxidase 1 P04041 Ms84 (2D) APAP
Peroxiredoxin-1 Q63716 Ct82, 84; Mt118, Ms90 (2D) TB, APAP
Peroxiredoxin-4 Q9Z0V5 Ms72, 75, 78 (2D) TB
Peroxiredoxin-6 O35244 Ct64, 67 (2D) TB, BHT, NAPH, MYCO,
ATRZ
Superoxide dismutase [Cu-Zn] P07632 Ct91, 94; Mt107, 109 (2D) BHT, TB, TIE
Thioredoxin P11232 Ct103, 104, 108 (2D) BB, TB, MCTP
Xenobiotic metabolism (13 proteins)
Cytochrome b5 P00173 Mt4 (1D), Ms104 (2D)
Cytochrome P450 2D26 P10634 Mt9 (1D)
Cytochrome P450 2E1 P05182 Mt9,10; Ms9 (1D) HAL
Glutathione S-transferase alpha-1 (ligandin) P00502 Ct6, Mt3, 5, 6 (1D) BB, MYCO
Glutathione S-transferase alpha-2 (ligandin) P04903 Ct1, 3-6 (1D) BB
Glutathione S-transferase alpha-3 P04904 Ct6, Mt6 (1D); Mt102 (2D) BB
Glutathione S-transferase Mu 1 P04905 Ct6, Mt6, Ms6 (1D); Ct76, Mt96,
Ms85 (2D)
BB, VCN, TB, TEU
Glutathione S-transferase Mu 2 P08010 Ct6, Mt6 (1D), Ct76, Mt102, Ms85
(2D)
BB, 4BP, TB
Glutathione S-transferase theta-2 P30713 Ct6, Mt6 (1D)
Glutathione S-transferase Yb-3 (GST mu-3) P08009 Ct6, Mt6 (1D)
Liver carboxylesterase 4 Q64573 Mt10 (1D) BB, HAL
UDP-glucuronosyltransferase 2B15 P36511 Mt9, Ms9 (1D)
UDP-glucuronosyltransferase 2B2 P08541 Mt10 (1D)
Apoptosis related proteins
Cytochrome c, somatic P62898 Mt135 (2D)
Mitochondrial fission 1 protein P84817 Mt4 (1D)
Miscellaneous proteins
Macrophage migration inhibitory factor P30904 Mt2 (1D) BB
Membrane-associated progesterone receptor component 1 P70580 Ms70 (2D)
a
UniProt protein databank accession number (www.uniprot.org).
b
Subcellular fraction where the protein was observed: Ct, cytosol; Mt, mitochondria; Ms, microsomes. Method used for protein separation: 1D,
SDS-PAGE (i.e. 1DGE); 2D, 2-dimensional electrophoresis (2DGE).













Koen et al. Page 23
c
Other chemicals whose reactive metabolites are also known to form adducts to proteins reported here to be targeted by TASO (http://
tpdb.medchem.ku.edu:8080/protein_database). Abbreviations used: ACRM, acrylamide; AMAP, 3-hydroxyacetanilide; APAP, acetaminophen;
ATRZ, atrazine; 4BP, bromophenol; BB, bromobenzene; BENZ, benzene; BFP, sarin analog; BHT, 2,5-di-tert-butyl-4-hydroxytoluene; BQ, 1,4-
benzoquinone; CAM, chloramphenicol; COC, cocaine; DACT, diaminochlorotriazine; DCE, 1,1-dichloroethylene; FCXC, flucloxacillin; HAL,
halothane; MCTP, monocrotaline pyrrole; MDAB, 3′-methyl-N,N-dimethyl-4-aminoazobenzene; MOL, molinate; MYCO, mycophenolic acid; 1,4-
NQ, 1,4-naphthoquinone; NAPH, naphthalene; TB, thiobenzamide; TEU, teucrine A; TFEC, S-(1,1,2,2-tetrafluoroethyl)-L-cysteine; TIE, tienilic
acid; VCN, acrylonitrile.
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